The French Competition Authority has handed down a fine of EUR 40 million to the Sanofi-Aventis Laboratory for implementing a practice of driving out competition by disparaging generic versions of its flagship product Plavix® to healthcare professionals in order to favor sales of the original product and Sanofi-Aventis’ own generic version, Clopidrogel Winthrop®. A complaint and a request for interim measures was filed against Sanofi-Aventis’ communication strategy by Téva Santé, French subsidiary of the world’s number 1 generic medicine producer. The
The French Competition Authority fines a pharmaceutical company for disparaging competing generics (Sanofi-Aventis)
L'accès à cet article est réservé aux abonnés
Déjà abonné ? Identifiez-vous
L’accès à cet article est réservé aux abonnés.
Lire gratuitement un article
Vous pouvez lire cet article gratuitement en vous inscrivant.